Steven Brugger

Steven Brugger brings over 35 years of experience in the biotech and pharmaceutical industry to Affinivax. He most recently served as the Chief Executive Officer of Visterra, a private biotech company which was acquired by Otsuka Pharmaceutical in September 2018. During his tenure at Visterra, Mr. Brugger led the company in closing a Series A round of financing, advancing its lead antibody program toward IND, and establishing strategic partnerships with both Pfizer and the Bill & Melinda Gates Foundation. Prior to Visterra, Mr. Brugger was the Chief Operating Officer at Momenta Pharmaceuticals. While at Momenta, he held several leadership roles as the company grew from a private start-up to a successful public-traded biotechnology company. Prior to Momenta, Mr. Brugger held various leadership and management positions at Millennium, Novartis, Ayerst, and Hoechst Pharmaceuticals. He received his BA in Biology from Susquehanna University and his MBA from the Rutgers Graduate School of Management.